Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
125,684,656
-
Total 13F shares
-
126,337,669
-
Share change
-
+4,880,497
-
Total reported value
-
$3,169,447,721
-
Put/Call ratio
-
26%
-
Price per share
-
$25.12
-
Number of holders
-
276
-
Value change
-
+$135,954,716
-
Number of buys
-
140
-
Number of sells
-
147
Institutional Holders of Apellis Pharmaceuticals, Inc. - Common Stock, $0.0001 par value (APLS) as of Q4 2025
As of 31 Dec 2025,
Apellis Pharmaceuticals, Inc. - Common Stock, $0.0001 par value (APLS) was held by
276 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
126,337,669 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, Avoro Capital Advisors LLC, VANGUARD GROUP INC, MORGAN STANLEY, Deep Track Capital, LP, RTW INVESTMENTS, LP, BlackRock, Inc., STATE STREET CORP, UBS Group AG, and SUVRETTA CAPITAL MANAGEMENT, LLC.
This page lists
276
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.